No Data
Qianjiang Yongan Pharmaceutical (002365.SZ): The holding subsidiary has obtained a food production license.
On March 6, Gelonghui reported that Qianjiang Yongan Pharmaceutical (002365.SZ) announced that its holding subsidiary, Hubei Ling'an Technology Co., Ltd., received a "Food Production License" issued by the Market Supervision Administration of Qianjiang City. Previously, Ling'an Technology mainly produced and sold polyhydric acid water-reducing agent monomers and water-reducing agents. In recent years, due to the poor condition of the Infrastructure Industry, Ling'an Technology has reported operational losses. To overcome this difficulty, Ling'an Technology actively engaged in new product development and business transformation, and has launched a new production line for "Monohydrate Creatine". This production line has now entered the trial run stage and is about to enter the project acceptance phase. The acquisition of this "Food Production License" mark.
Qianjiang Yongan Pharmaceutical (002365.SZ): has cumulatively repurchased 1.88% of shares.
Gelonghui reported on March 3 that Qianjiang Yongan Pharmaceutical (002365.SZ) announced that as of the end of February 2025, the company has repurchased a total of 5,537,350 shares through centralized bidding, accounting for 1.88% of the company's total share capital, with a highest Fill Price of 7.90 yuan/share, a lowest Fill Price of 6.67 yuan/share, and a total transaction amount of 40.45455 million yuan (excluding transaction fees).
Yongan Pharmaceutical: 2024 Annual Results Forecast
Qianjiang Yongan Pharmaceutical (002365.SZ) signed a framework agreement for equipment processing and manufacturing for the year 2025 with Hubei Yongbang.
Qianjiang Yongan Pharmaceutical (002365.SZ) released an announcement, stating that the company ("Party A") has entered into an agreement with Hubei Yongbang Engineering Technology Co., Ltd....
Qianjiang Yongan Pharmaceutical (002365.SZ): The invested company is currently not producing carbon nanotubes.
On December 13, Gelonghui reported that Qianjiang Yongan Pharmaceutical (002365.SZ) stated on the investor interaction platform that its invested company, Wuhan Low-Dimensional, is currently focusing on the heating field of carbon-based materials and is not producing carbon nanotubes or any Solid State Battery related products.
Qianjiang Yongan Pharmaceutical (002365.SZ): has received an invention patent certificate.
On November 29, Gelonhui reported that qianjiang yongan pharmaceutical (002365.SZ) announced that the company recently received an invention patent certificate issued by the National Intellectual Property Administration, with the invention titled 'a method and system for removing impurities in taurine mother liquor recycling.'
Benign Growth For Qianjiang Yongan Pharmaceutical Co., Ltd. (SZSE:002365) Underpins Stock's 27% Plummet